Biocytogen completed over 900 target antibody discovery projects (with 40+ in the PCC to IND stages), establishing a library of over 400K fully human antibody sequences available for evaluation and out-licensing to pharmaceutical and biotechnology companies.

Screened monoclonal antibodies can also be developed as bispecific/multispecific antibodies, cell engagers, bispecific antibody-drug conjugates (bsADCs), nanobodies, TCR-mimic antibodies, and cell therapies.

We are now offering out-licensing and co-development opportunities for these antibodies to the global biopharmaceutical community. Contact us at BD-Licensing@biocytogen.com for more details about our assets available for your target.